Department of Endocrinology, Hainan Wanning People's Hospital, Wanning, China.
Department of Pharmacy, Danzhou People's Hospital, Danzhou, China.
Ann Palliat Med. 2022 Mar;11(3):1028-1037. doi: 10.21037/apm-22-121.
There were reports that many patients with type 2 diabetes mellitus (T2DM) could not maintain the normal level of glycemic, who were treated with the antidiabetic agents. The sodium-glucose co-transporter-2 (SGLT2) inhibitors could improve patients' blood glucose level by inducing glycosuria, improving insulin sensitivity and the function of β-cell and decreasing glucose toxicity. Which was unlike with other agents, indicating that the SGLT2 inhibitors might be effective alone or in combination with any other drugs. As a SGLT2 inhibitor, Dapagliflozin could be used in patients with T2DM.
Studies' identification were conducted with the literature search, and we searched studies published between 1950 and 2021 in PubMed, the Cochrane Library and Embase. A meta-analysis was performed using RevMan 5.3 software. Continuous data are presented as the means and standard deviations of differences in performance before and after active or control interventions. Adverse events were also assessed.
Fifteen studies that provided individual data were included. Treatment with dapagliflozin was compared with treatment with placebo and resulted in a significantly greater change in HbA1c levels, fasting plasma glucose (FPG) and weight. In terms of the incidence of adverse drug reactions, the incidence of hypoglycemic events was not significantly different between the experimental and control groups. However, the incidences of genital infection and urinary tract infection were higher in the experimental group than in the control group.
According to the available data, dapagliflozin combined with oral hypoglycemic agents can effectively reduce the level of HbA1c and body weight; however, it does not increase the incidence of hypoglycemia but can cause urinary tract infection and genital infection. Due to the limited literature included, the above conclusions need to be verified through more high-quality studies.
有报道称，许多 2 型糖尿病（T2DM）患者在使用降糖药物治疗后无法维持正常的血糖水平。钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂通过诱导尿糖、改善胰岛素敏感性和β细胞功能以及降低葡萄糖毒性来改善患者的血糖水平。这与其他药物不同，表明 SGLT2 抑制剂可能单独或与任何其他药物联合使用有效。达格列净作为一种 SGLT2 抑制剂，可用于 T2DM 患者。
通过文献检索对研究进行了识别，我们在 PubMed、Cochrane 图书馆和 Embase 中检索了 1950 年至 2021 年间发表的研究。使用 RevMan 5.3 软件进行荟萃分析。连续数据以活性或对照干预前后表现的均值和标准差差异表示。还评估了不良事件。
纳入了 15 项提供个体数据的研究。与安慰剂相比，达格列净治疗可显著降低 HbA1c 水平、空腹血糖（FPG）和体重。就不良反应发生率而言，实验组与对照组低血糖事件发生率无显著差异。然而，实验组生殖道感染和尿路感染的发生率高于对照组。
根据现有数据，达格列净联合口服降糖药可有效降低 HbA1c 水平和体重；但不会增加低血糖的发生率，反而会引起尿路感染和生殖道感染。由于纳入的文献有限，上述结论需要通过更多高质量的研究来验证。
